# FDA Approves Accord BioPharma Biologic; Entry Expected to Intensify Market Competition Accord BioPharma Inc. has received FDA approval for a new biologic therapeutic under BLA761452, positioning the company to compete in an increasingly crowded market segment and potentially pressuring pricing and market share dynamics for existing competitors. The approval expands Accord's portfolio and may accelerate consolidation trends within the specialty biopharmaceutical sector as companies vie for therapeutic dominance.